Clinical Trial Update: Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients [Phase 1]

View source ↗

Summary

Phase 1, placebo-controlled, dose-escalation study assessing the safety of IMO-2125 in hepatitis C patients; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• IMO-2125 (IMO-2125)

Snippet

Sponsor: Idera Pharmaceuticals, Inc. | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED | Results posted: 2019-02-15